Kintara Therapeutics, Inc. says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has now been activated in 15 US sites
The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for...